Financial Data and Key Metrics Changes - The company reported product revenue of $2.9 million in Q1 2026, a decrease from $3.3 million in Q1 2025, but a sequential increase of 5.5% from $2.7 million in Q4 2025 [11] - Product gross profit was $1.6 million, or 54.2% of revenue, in Q1 2026, compared to $1.9 million, or 58.9% of revenue, in the same quarter of the prior year [12] - The net loss for Q1 2026 was $1.4 million, or a loss of $0.03 per share, compared to net income of $1.8 million, or $0.06 per share, in Q1 2025 [13] Business Line Data and Key Metrics Changes - The OneRF brain ablation system saw nearly half of all ablations performed since its launch in Q1 2026, indicating strong market adoption [4] - The OneRF trigeminal nerve ablation system initiated a limited commercial launch in Q1 2026, with nine patients treated across three centers, all reporting pain relief [5][6] Market Data and Key Metrics Changes - The company is working towards receiving ISO 13485 certification to facilitate international commercialization of its technology [5] - The company attended the American Epilepsy Society meeting, showcasing its technology and receiving positive feedback from medical professionals [4] Company Strategy and Development Direction - The company is projecting fiscal year 2026 sales to be at least $10.5 million, representing a minimum 17% increase from fiscal year 2025 [3] - The company is in discussions with strategic partners for potential licensing of its technology and aims to conclude these discussions quickly [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued positive momentum from fiscal year 2025 and the progress across all programs [3] - The company is focused on capturing long-term outcomes through a registry for patients treated with its systems, which will help validate the technology's effectiveness [4][31] Other Important Information - The company appointed Jason Mills to its board of directors, bringing valuable experience from his previous roles in strategy and investment banking [10] - As of December 31, 2025, the company had cash and cash equivalents of $3.6 million and no outstanding debt [13][14] Q&A Session Summary Question: Update on trigeminal nerve ablation cases - The nine cases were performed at three centers, with all patients reporting pain relief. Discussions are ongoing with strategic partners for commercialization [20][21] Question: Expectations for operating expenses - SG&A expenses are expected to remain flat for the rest of the year, while R&D expenses may fluctuate based on project phases [23][25] Question: Clinical feedback from neurologists - Feedback indicates success in reducing seizures or eliminating them, with procedures being performed at patients' bedsides [30][32] Question: Sales and marketing responsibilities - Zimmer is responsible for all marketing and sales costs, while the company provides training and field support [35]